ArticleClinical transplantation2026
Long-Term Endocrine Effects of Hematopoietic Stem Cell Transplantation in Children: A Reappraisal.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) is widely used in both malignant and non-malignant diseases in children. This study aimed to evaluate long-term endocrine complications in pediatric HSCT survivors.
methodsChildren who underwent HSCT between April 2010 and October 2014 were retrospectively assessed. Data included demographics, growth and nutritional status, thyroid function, bone health, pubertal development, and gonadal function.
resultsSeventy-five patients (45 males, 30 females; mean current age 18.8 ± 3.9 years) were included. The mean follow-up duration after HSCT was 9.7 ± 1.2 years, and at least one endocrine disorder was identified in 40 patients (53.3%). At the last follow-up, 23 patients (30.6%) were underweight, and 17 (18.6%) had short stature. Growth impairment was more frequent in patients with non-malignant diseases. Hypothyroidism was observed in 6 patients (8%), and low bone mineral density (BMD)/osteoporosis in 17 (22.6%). Short stature, malnutrition, low BMD, and vitamin D deficiency were more prevalent among those who underwent HSCT at ≥10 years of age. Hypogonadism was detected in 12 females (40%) and 11 males (24%) and showed no association with age at HSCT, pubertal stage, primary diagnosis, or conditioning regimen.
conclusionsThese findings underscore the importance of long-term endocrine surveillance in HSCT survivors, particularly in those transplanted at ≥10 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.